Xylo Bio
@Xylo_Bio
Followers
1K
Following
1K
Media
164
Statuses
858
Transforming Lives with Targeted Neurotherapeutics. This account is no longer active. For updates, head to https://t.co/dNIu5TKZoP
Learn more ➜
Joined June 2021
🚨 We’re officially Xylo Bio!. New name, sharper focus: advancing neuroplastogens to restore brain function. XYL-1001 moves toward clinical trials + new board members. We’re entering an exciting new chapter!. 📢 Read more: #Biotech #Neurotherapeutics
2
3
9
RT @startmate: 💜 WE VISITED @Psylo_Bio 💜 . Last week, co-founder of @Psylo_Bio, Josh Ismin invited the community into the @Psylo_Bio labs!….
0
1
0
RT @BrainMind_Usyd: Congrats to Dr @neuronick_ @Psylo_Bio, @TesseraTx awarded $3 million in a CRC-P grant to develop novel neuroplastogens….
0
2
0
RT @Sydney_Science: 2 @Sydney_Uni researchers secure $6M from @CoopResearchAus!. ⭐️Cameron Kepert will develop advanced materials for effic….
0
5
0
Psylo is joining forces with Tessara Therapeutics & @Sydney_Uni to advance neuroplastogen development for treating addiction! 🚀🧠 . We aim to reshape and ‘rewire’ how we tackle substance use disorders. Learn more:
1
7
13
Non-hallucinogenic psychedelics are challenging the idea that 'tripping' is essential for therapeutic benefits. As they are investigated for various mental health conditions like depression and addiction, they could redefine mental health treatments.
1
0
1
J&J’s ketamine-derived drug, Spravato, is gaining traction as a treatment for depression, especially in cases where other therapies fail. Despite early regulatory hurdles and the pandemic, over 2,800 clinics now offer spravato and sales are expected to surpass $1B this year.
1
0
1
Innovative trial will use psilocybin-assisted therapy to target relapse in opioid addiction @imperialcollege .
1
0
0
Psilocybin as an alternative treatment for depression: “The more flexible a patient’s brain was 3 weeks after 1 trip, the better their outcome on depression at 6 months,” Prof Nutt said, suggesting cognitive flexibility as a possible therapeutic mechanism.
3
0
0
RT @BrandtAsher: The binding modes of serotonin 2A agonists (blue) vs. antagonists (red) are clear when superimposed. Antagonists occupy sp….
0
1
0
Psylo's Neuroscience Newsletter, September 🧠 - New findings in anxiety, depression and addiction, brain connectivity, predicting efficacy, sex differences, neuroplasticity, new tools, and exploring molecular targets of psychedelics beyond 5-HT2A.
0
2
5
RT @DilaraB_PhD: Or if you're attending the 7th Neuropsychiatric Drug Development Summit, don't miss our panel on navigating the commercial….
0
1
0
Excited to see Dr. @WillJorgo, Psylo's Director of Medicinal Chemistry, presenting at the @ASCEPTanz meeting this week! . Will is a highly accomplished EMCR with a wealth of experience across academia, industry, and startups. Don't miss it! #ASCEPT2024.
Registrations now open for the @ASCEPTanz 2024 Drug Discovery SIG Student & ECR virtual symposium. Abstract submission closes 14th August.
0
0
2
Blood-Brain Barrier Modulation and #Neuroplasticity. Neuronal activity increased #BBB permeability in the somatosensory cortex, which was linked to long-term synaptic plasticity; study of rats combined with human MRI imaging. #ICYMI #Research
0
0
0